PremiumThe FlyWave Life Sciences reports Q1 EPS (29c), consensus (26c) Controversial doctor Vinay Prasad named CBER director, STAT reports WVE Upcoming Earnings Report: What to Expect? PremiumThe FlyRBC sees Makary interview as potentially positive for biotech stocks Wave Life Sciences price target lowered to $19 from $22 at B. Riley Wedbush starts RNA-focused standout Wave Life Sciences with an Outperform PremiumThe FlyWave Life Sciences announces data from Phase 2 FORWARD-53 trial of WVE-N531 Korro Bio price target lowered to $95 from $105 at RBC Capital Promising Pipeline Developments and Strategic Advancements Support Buy Rating for Wave Life Sciences 
